companydata.dkcompanydata.dk

Hoba Therapeutics ApS: Financial statements 2018

CVR: 38231170

Source: annual report 2018, Danish Business Authority

01/04/2017 – 31/03/2018

Hoba Therapeutics ApS (CVR 38231170) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 485,419 and a net result of DKK -891,853. Equity in the 2018 report amounted to DKK 8,855,810. The solvency ratio was 85.3%.

Gross Profit
DKK 485,419
Profit/Loss
DKK -891,853
Equity
DKK 8,855,810
Total Assets
DKK 10,383,472

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Steen Palle Petersen joins the board of Hoba Therapeutics ApSNov 19, 2018

As of November 19, 2018, Steen Palle Petersen has joined the board of directors of Hoba Therapeutics ApS.

Lene Gerlach leaves the board of Hoba Therapeutics ApSNov 19, 2018

As of November 19, 2018, Lene Gerlach has left the board of directors of Hoba Therapeutics ApS.

About Hoba Therapeutics ApS

Hoba Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade. The board consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and Gunnar Magnus Severus Modée Persson. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund. The company has 2 employees (2026). In 2026, the company reported a gross profit of DKK -61,710,701 and a net result of DKK -67,693,868 compared with DKK -43,008,287 the year before. Equity in the 2026 report amounted to DKK 1,143,899.

Source: annual report 2026, Danish Business Authority